Glivec Research Today is a free monthly online journal that collates and summarizes the latest research about Glivec, including details on gleevec, imatinib, cancer, treatment, side-effects.

Volume 5 (2008), Issue 5 (May)

1. Therapy adapted to molecular response in patients with chronic myelogenous leukaemia in first chronic phase: results of the Duesseldorf study.
   Hematol Oncol. [Abstract] [Full-text]
2. The effect of P-gp (Mdr1a/1b), BCRP (Bcrp1) and P-gp/BCRP inhibitors on the in vivo absorption, distribution, metabolism and excretion of imatinib.
   Invest New Drugs. [Abstract] [Full-text]
3. Therapy options in imatinib failures.
   Oncologist, 13(4): 424-34. [Abstract] [Full-text]
4. Emergence of therapy-unrelated CML on a background of BCR-ABL-negative JAK2V617F-positive chronic idiopathic myelofibrosis.
   Leuk Res. [Abstract] [Full-text]
5. Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-alpha: 5-year outcome.
   Haematologica, 93(5): 770-4. [Abstract] [Full-text]
6. Phospho-CRKL monitoring for the assessment of BCR-ABL activity in imatinib-resistant chronic myeloid leukemia or Ph+ acute lymphoblastic leukemia patients treated with nilotinib.
   Haematologica, 93(5): 765-9. [Abstract] [Full-text]
7. Characterization of compound 584, an Abl kinase inhibitor with lasting effects.
   Haematologica, 93(5): 653-61. [Abstract] [Full-text]
8. Chronic myeloid leukemia and HIV-infection.
   Leuk Lymphoma. [Abstract] [Full-text]
9. Phase II, Open-Label Study Evaluating the Activity of Imatinib in Treating Life-Threatening Malignancies Known to Be Associated with Imatinib-Sensitive Tyrosine Kinases.
   Clin Cancer Res, 14(9): 2717-2725. [Abstract] [Full-text]
10. Molecular monitoring in chronic myeloid leukemia: response to tyrosine kinase inhibitors and prognostic implications.
    Cancer, 112(10): 2112-8. [Abstract] [Full-text]
11. Platelet-derived growth factor receptor as a prognostic marker and a therapeutic target for imatinib mesylate therapy in osteosarcoma.
    Cancer, 112(10): 2119-29. [Abstract] [Full-text]
12. Simple segmental resection of the second portion of the duodenum for the treatment of gastrointestinal stromal tumors.
    Langenbecks Arch Surg, 393(4): 605-9. [Abstract] [Full-text]
13. MEK inhibitor enhances the inhibitory effect of imatinib on pancreatic cancer cell growth.
    Cancer Lett, 264(2): 241-9. [Abstract] [Full-text]
14. Common features of myeloproliferative disorders with t(8;9)(p12;q33) and CEP110-FGFR1 fusion: report of a new case and review of the literature.
    Leuk Res, 32(8): 1304-8. [Abstract] [Full-text]
15. Tailoring tyrosine kinase inhibitor therapy to tackle specific BCR-ABL1 mutant clones.
    Leuk Res, 32(8): 1313-6. [Abstract] [Full-text]
16. Multiple myeloma cells directly stimulate bone resorption in vitro by down-regulating mature osteoclast apoptosis.
    Leuk Res, 32(8): 1279-87. [Abstract] [Full-text]
17. Safe treatment of a patient with CML using dasatinib after prior retinal oedema due to imatinib.
    Leuk Res. [Abstract] [Full-text]
18. Effects of chemotherapy during pregnancy on the placenta.
    Pediatr Dev Pathol. [Abstract] [Full-text]
19. Leiomyosarcoma originating from the superior mesenteric vein: a case report and review of the literature.
    Ann Vasc Surg, 22(3): 453-5. [Abstract] [Full-text]
20. Ki11502, a novel multitargeted receptor tyrosine kinase inhibitor, induces growth arrest and apoptosis of human leukemia cells in vitro and in vivo.
    Blood, 111(10): 5086-92. [Abstract] [Full-text]
21. Complete molecular responses are achieved after reduced intensity stem cell transplantation and donor lymphocyte infusion in chronic myeloid leukemia.
    Blood, 111(10): 5252-5. [Abstract] [Full-text]
22. Novel treatment of ovarian cancer cell lines with Imatinib mesylate combined with Paclitaxel and Carboplatin leads to receptor-mediated antiproliferative effects.
    J Cancer Res Clin Oncol. [Abstract] [Full-text]
23. Nilotinib and donor lymphocyte infusion in the treatment of Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) relapsing after allogeneic stem cell transplantation and resistant to imatinib.
    Leuk Res. [Abstract] [Full-text]
24. The cytotoxicity of a Grb2-SH3 inhibitor in Bcr-Abl positive K562 cells.
    Biochem Pharmacol, 75(11): 2080-91. [Abstract] [Full-text]
25. Leukemia-associated antigens as target structures for a specific immunotherapy in chronic myeloid leukemia.
    Eur J Haematol, 80(6): 461-8. [Abstract] [Full-text]
26. Multiple intracranial tumors in Philadelphia chromosome positive acute lymphoblastic leukemia: successful treatment following aggressive supportive care, early cranial radiation, high dose chemotherapy and imatinib.
    Pediatr Blood Cancer, 51(1): 135-7. [Abstract] [Full-text]
27. Effects of imatinib mesylate on spontaneous electrical and mechanical activity in smooth muscle of the guinea-pig stomach.
    Br J Pharmacol, 154(2): 451-9. [Abstract] [Full-text]
28. Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability.
    Br J Cancer, 98(10): 1633-40. [Abstract] [Full-text]
29. Imatinib resistance in a novel translocation der(17)t(1;17)(q25;p13) with loss of TP53 but without BCR/ABL kinase domain mutation in chronic myelogenous leukemia.
    Cancer Genet Cytogenet, 183(1): 77-81. [Abstract] [Full-text]
30. Experimental non-ATP-competitive therapies for chronic myelogenous leukemia.
    Leukemia, 22(5): 932-40. [Abstract] [Full-text]
31. Sphingosine kinase-1 is a downstream regulator of imatinib-induced apoptosis in chronic myeloid leukemia cells.
    Leukemia, 22(5): 971-9. [Abstract] [Full-text]
32. Effects of imatinib (Glivec) on the pharmacokinetics of metoprolol, a CYP2D6 substrate, in Chinese patients with chronic myelogenous leukaemia.
    Br J Clin Pharmacol, 65(6): 885-92. [Abstract] [Full-text]
33. Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia.
    Blood. [Abstract] [Full-text]
34. BCR-ABL oncogenic transformation of NIH 3T3 fibroblasts requires the IL-3 receptor.
    Oncogene, 27(22): 3194-200. [Abstract] [Full-text]
35. Histologic studies of the intraocular toxicity of imatinib mesylate in rabbits.
    Eye, 22(5): 712-4. [Abstract] [Full-text]
36. Uterine Contractions Depend on KIT-Positive Interstitial Cells in the Mouse: Genetic and Pharmacological Evidence.
    Biol Reprod. [Abstract] [Full-text]
37. Activity of a novel Aurora kinase inhibitor against the T315I mutant form of BCR-ABL: in vitro and in vivo studies.
    Cancer Sci, 99(6): 1251-7. [Abstract] [Full-text]
38. Six years survival on imatinib with no disease progression after diagnosis of metastatic duodenal gastrointestinal stromal tumour: A case report.
    J Med Case Reports, 2: 110. [Abstract] [Full-text]
39. Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells.
    Mol Cancer Ther, 7(5): 1121-9. [Abstract] [Full-text]
40. Molecular characterization of pediatric gastrointestinal stromal tumors.
    Clin Cancer Res, 14(10): 3204-15. [Abstract] [Full-text]
41. Interaction of imatinib with human organic ion carriers.
    Clin Cancer Res, 14(10): 3141-8. [Abstract] [Full-text]
42. Inhibition of mitochondrial metabolism by methyl-2-cyano-3,12-dioxooleana-1,9-diene-28-oate induces apoptotic or autophagic cell death in chronic myeloid leukemia cells.
    Mol Cancer Ther, 7(5): 1130-9. [Abstract] [Full-text]
43. Comparison of antitumor effects of multitargeted tyrosine kinase inhibitors in acute myelogenous leukemia.
    Mol Cancer Ther, 7(5): 1110-20. [Abstract] [Full-text]
44. Combi-targeting concept: an optimized single-molecule dual-targeting model for the treatment of chronic myelogenous leukemia.
    Mol Cancer Ther, 7(5): 1033-43. [Abstract] [Full-text]
45. Anti-apoptotic action of Wnt5a in dermal fibroblasts is mediated by the PKA signaling pathways.
    Cell Signal, 20(7): 1256-66. [Abstract] [Full-text]
46. Absence of gene mutations in KIT-positive thymic epithelial tumors.
    Lung Cancer. [Abstract] [Full-text]
47. Improving chemotherapeutic drug penetration in melanoma by imatinib mesylate.
    J Dermatol Sci. [Abstract] [Full-text]
48. Expression of C-kit and Platelet-Derived Growth Factor Receptors in Ovarian Granulosa Cell Tumors.
    Reprod Sci. [Abstract] [Full-text]
49. New Bcr-Abl inhibitors in chronic myeloid leukemia: keeping resistance in check.
    Expert Opin Investig Drugs, 17(6): 865-78. [Abstract] [Full-text]
50. An evaluation of the cardiotoxicity of imatinib mesylate.
    Leuk Res. [Abstract] [Full-text]
51. The Src/ABL kinase inhibitor dasatinib (BMS-354825) inhibits function of normal human T-lymphocytes in vitro.
    Clin Immunol, 127(3): 330-9. [Abstract] [Full-text]
52. Development and dynamics of robust T-cell responses to CML under imatinib treatment.
    Blood, 111(11): 5342-9. [Abstract] [Full-text]
53. Heart failure associated with sunitinib malate: a multitargeted receptor tyrosine kinase inhibitor.
    Cancer, 112(11): 2500-8. [Abstract] [Full-text]
54. Turning promiscuous kinase inhibitors into safer drugs.
    Trends Biotechnol, 26(6): 295-301. [Abstract] [Full-text]
55. Effect of antacid on imatinib absorption.
    Cancer Chemother Pharmacol. [Abstract] [Full-text]
56. Galangin increases the cytotoxic activity of imatinib mesylate in imatinib-sensitive and imatinib-resistant Bcr-Abl expressing leukemia cells.
    Cancer Lett, 265(2): 289-97. [Abstract] [Full-text]
57. Simultaneous occurrence of t(9;22)(q34;q11.2) and t(16;16)(p13;q22) in a patient with chronic myeloid leukemia in blastic phase.
    Cancer Genet Cytogenet, 183(2): 109-13. [Abstract] [Full-text]
58. Unusually large extraintestinal GIST presenting as an abdomino-pelvic tumor.
    Arch Gynecol Obstet, 278(1): 89-92. [Abstract] [Full-text]
59. Characteristics of KIT-negative gastrointestinal stromal tumours and diagnostic utility of protein kinase C theta immunostaining.
    J Clin Pathol, 61(6): 722-9. [Abstract] [Full-text]
60. KIT overexpression induces proliferation in astrocytes in an imatinib-responsive manner and associates with proliferation index in gliomas.
    Int J Cancer. [Abstract] [Full-text]
61. A pharmaco-economic analysis of second-line treatment with imatinib or sunitinib in patients with advanced gastrointestinal stromal tumours.
    Br J Cancer, 98(11): 1762-8. [Abstract] [Full-text]
62. Imatinib mesylate inhibits proliferation and exerts an antifibrotic effect in human breast stroma fibroblasts.
    Mol Cancer Res, 6(5): 706-14. [Abstract] [Full-text]
63. Pregnancy complicated with chronic myelogeneous leukemia (CML) successfully treated with imatinib: a case report.
    Arch Gynecol Obstet, 278(2): 161-3. [Abstract] [Full-text]
64. Intracranial recurrence and distant metastasis of scalp dermatofibrosarcoma protuberans.
    J Neurooncol, 88(3): 305-8. [Abstract] [Full-text]

© 2004-2008 Glivec Research Today. All Rights Reserved.